

ONCOGENIC POTENTIAL OF HUMAN PAPILLOMAVIRUS

Dr. Chintan Himmatbhai Desai*

C/1124, Green Park Society, Kaliyabid, Bhavnagar, Gujarat.

Received date: 12 March 2020

Revised date: 01 April 2021

Accepted date: 22 April 2021

*Corresponding author: Dr. Chintan Himmatbhai Desai

C/1124, Green Park Society, Kaliyabid, Bhavnagar, Gujarat.

ABSTRACT

Human Papillomavirus (HPV) is the most common cause of cervical cancer. Cervical cancer being the second most common cancer after lung cancer, affecting women of different age groups; has a prevalence of about 20% in young sexually active women. Among different types of HPV, HPV16 the major strain causing this cancer and is sexually transmitted had been unnoticed for decades. Keeping in mind the multiple risk factors related with cervical cancer such as early age sexual activities, teenage pregnancies, smoking, use of oral contraceptives, having multiple sex partners, hormone replacement therapies and various other unknown factors lead to the onset of the disease. Awareness for various diagnostic procedures such as Pap smears screening prove to be an effective way in eradicating the oncogenic potential of HPV.

KEYWORDS:

BACKGROUND

Human papilloma viruses (HPV) are small non enveloped virus containing double stranded DNA as their genetic material and are about 55 nm in size. Their genome has three functional coding regions; E: a gene coding early viral function, L: a gene coding late viral function and LCR: a long control region which lies between E and L. They appear to show similarity with polyoma viruses and consist of about 72 capsomeres. The papilloma viruses and its viral nature were first seen in human warts in 1907, and the first papilloma virus was isolated from a rabbit that was identified by Richard Shoppe in the year 1983. Even it was an early start for the detection of human papilloma viruses; this topic remained closed till 1970's. Studies related with papilloma viruses were allowed to move forth only when cervical cancer's proximity with HPV was proved and with its increasing significance in the field of molecular virology.^[1]

Human papilloma virus is known to be the main reason for cervical carcinomas. Back in 1976 HPV was seen with its involvement in the successful development of cervical tumors and since then various epidemiological and biological statistics has justified this observation.^[2] HPV viruses are one of the most common viruses which are transmitted sexually and are found in both men and women. Its ratio is much higher in western countries as compared to other regions of the world.

Prevalence and Incidence


Cervical cancer as the most prevalent cancer in women in the coming years is the main cause of death, especially in young women. Its ratio varies all over the world, but a significantly high ratio has been seen in the western countries. By statistical and geographical analysis, it proves to be higher in Native American women than in Caucasian women. It was also found common in Hispanic and African American women.^[3] According to the World Health Organization (WHO) statistics, there are approximately 500,000 new cases registered each year out of which 250,000 cases are fatal. This alarming situation in the coming years for papillomaviruses has lead molecular virologists worldwide to go deep into pathogenesis and bring out solutions to its therapeutic potential.^[4] According to the most recent reports, in the United States of America (USA) women are prone to this infection twice than men in all regions of the world including USA and the prevalence of HPV is much higher in women than men. The reported overall prevalence rate of HPV in women irrespective of races was 17.9%, while men showed a comparably lower rate of 8%. African Americans had the ratio of 20 to 29% as Caucasians and their prevalence rate was known to be about 12.5%. People who had multiple sex partners during their lifetime were on a higher risk of HPV infection as the frequency of HPV was seen to be 20.1% compared 7% in those patients who had only one sexual partner throughout their sexual lives.^[5]

Different types of HPV

About 100 different subtypes of HPV with distinguished variations in its genetic and oncogenic potential are known. The subtypes which specifically affect the anogenital tract are HPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66 and 69.^[3] These specific subtypes can be further classified or described under high-risk and low-risk parameters. These specific subtypes possess a remarkable ability to cause malignancy and play a pivotal role in development of various tumors.^[2] The HPV type 6 and 11 are considered as the low risk genital types while on the other hand HPV 16 and 18 contribute towards malignancy and fall under the high risk genital types.^[6] Prior to a confirmed malignancy of the cervical region, there appears a cervical intraepithelial neoplasia (CIN) which can indicate it towards a high risk HPV infection and this infection is actually the prolonged interval with specific symptoms till the development of a tumor.^[2] It is now an established fact that papillomaviruses are highly species specific.

Structure of HPV 16

HPV16 is one of the most prominent strains of HPV which is typically classified under high risk type infection as mentioned earlier. It is associated with additional infections namely lichen sclerosis and not only it leads to cervical cancer but is also related with vaginal, vulval, anal and penile cancers or benign growths specifically in these areas, but the most prominent and hazardous damage caused by HPV 16 strain is cervical cancer.^[7] The HPV 16 is a small non enveloped virus containing double stranded DNA as its genetic material. Its genome has seven functional coding regions; E1/E2: Code proteins that control the function of E6 and E7 genes, E4: a gene coding a protein the function of this protein is largely unknown but may control virus release from cell, E5: codes for a hydrophobic protein which enhances immortalization of the cell, E6: gene coding proteins which inhibit negative regulators of the cell cycle and further inhibit p53 which is a transcription factor for apoptosis, E7: codes for viral protein that bind to the retinoblastoma tumor suppressor proteins thereby permitting the cell to progress through the cell cycle in the absence of normal mitogenic signals, L1/ L2: Code for structural proteins for late viral and formation of complete virus particles and LCR: a long control region which lies between E and L that is necessary for normal virus replication and control of gene expression (Figure 1).



The figure shows the location of the major open reading frames which possess the ability to encode proteins and the long control regions which have the ability of transcription and replication control elements (Adapted from Molecular biologists for Oncologists.1996, 2nd edd., Editors "J.R.Yarnold, M.R.Stratton, T.J.McmMillan" publishers, Chapman and Hall).

Pathogenesis of HPV 16 and its Replication

Replication of HPV 16 is initiated with the replication of viral DNA in contrast with the cellular chromosomes. In this process of division, one daughter cell moves apart from the basal lamina to undergo differentiation. Infection in the basal lamina can persist for years because, of the restriction of virion production to only differentiated cells. The E1 and E2 proteins are supposed to be the recognition factors and regulators for early viral transcription. Icosahedral capsid for virion generation are formed by L1 and L2.^[1]

HPV 16 affects approximately 20% of the adult population particularly in western countries.^[8] It sometimes causes warts which are flat in appearance called condyloma planum and they appear to be less visible. Others include cauliflower like warts mostly seen in the genital areas.^[9] The three major onco-proteins which have gained importance in HPV and its relation with cervical cancer are E5, E6, E7 respectively. These proteins are associated with cervical cancer studied *both in vitro and in vivo*.^[10] The proteins E6 and E7 are important for the inhibition of tumor suppressor genes namely p53 and pRb.^[11] As far as E5 is concerned it is known to have weak oncogenic properties which result in increased activity of epidermal growth factor receptor (EGFR) and there by inhibiting the major histocompatibility complex expression.^[11] For a crucial step to initiate in carcinogenesis it is very necessary that the viral DNA integrates into the host genome. To understand this concept of integration leading to malignancy it is very important to jot down that E2 and E1 are the two proteins which play a leading role in control of transcription and replication and in the absence or loss of activity of these proteins deregulation of E6 and E7 onco-proteins results.^[12]

HPV I6 E6 protein comprises of about 151 amino acids, these proteins are confined to the nuclear matrix and non-nuclear membrane fraction. Their major function is in zinc binding. This E6 protein is related with high-risk HPV associated with wild type p53 tumour suppressor protein. To get associated with p53, the E6 protein needs a cellular protein of about 100-kDa and is known as E6-AP.^[13] The E6 protein favours abnormal cell growth by the process of binding and rapidly targeting the p53 protein.^[14] This p53 protein shows degradation by the ubiquitin pathway and the cell is allowed to go from the p53 associated negative growth control.^[15] The E6-E6 AP complex specifically target ubiquitin targeted substrates. It also shows p53 disruption and p53 mediated apoptosis.^[16] HPV E7 proteins are small proteins consisting of 98 amino acids and zinc binding phosphoproteins are confined in the nucleus. This high-risk HPV E7 protein has a higher binding affinity for pRb protein.^[17]

The mutational analysis reveals that an E7 protein plays a major role in transformation and has proved its ability with interference with pRb function. This interference of E7 protein with the pRb function contributes in the development of malignancy. pRb is also a tumour suppressor gene and is the main mutant allele of Rb present in the germline of an individual which is linked to a predisposition to retinal tumour.^[18] The major finding that how pRb functions in growth control lies with the proof of its binding ability and inhibition of various transcription factors namely E2 F-1 and cMyc proteins. These cMyc and E2 F-1 proteins activate some of the essential genes which are required for DNA synthesis. The HPV infected cell typically shows that pRb is inactive throughout in association with binding of the E7 proteins. This decreased or inappropriate release of transcription factors favours the deregulated expression of genes which are related with normal control and cell division.^[19]

More striking evidence reported by several studies is that E7 possesses and has the capability of overcoming DNA damage induced p53-dependant G1 arrest. In the precancerous lesions the loss of control point favours and allows the DNA damaged cells to enter the normal cell division initiating to cancerous or tumourigenic mutations. This evidence of mutations is well supported by recent reports that deregulate expression of E2 F in rat fibroblasts which leads to S phase entry in the cell cycle and apoptosis in p53.^[20] Moreover, expression of high risk HPV oncogenes in this DNA damage response is most probably interfered or disrupted at two points. At first the E6 protein by targeting the p53 protein for degradation inhibits the transcriptional activation of the kinase inhibitor and secondly expression of the E7 proteins can result in the constitutive inactivation of pRb and hence the deregulation of E2 F1 takes place.^[20]

Many reviews and studies had focused on the mechanisms and significant properties of E6 and E7

proteins and it is very essential to bring into light the detailed analysis of these studies on the specific regions of HPV16 E7 proteins.^[6] For mapping the contribution of these particular events of the protein sequence point mutations and deletions were used. In vitro studies have revealed that the biological properties of HPV16 E7 are also related with in vivo functions which include immortalization and transformation alone or in cooperation with ras.

Causes of HPV16

As far as the causes of HPV16/HPV18 are concerned sexual behaviour is the strongest factor for this increasing malignancy. Despite sexual behaviour other factors might also be involved in its infection. It is important to note that all HPV infections does not lead to a malignancy however, the two strains of HPV that are HPV16 and HPV18 mainly contributes in the development of cervical cancer. Other factors include smoking, extensive use of oral contraceptives and history of having sexually transmitted diseases.^[21] Mutations in ras, fos and other related oncogenes has also been detected in cervical cancer cell lines, but their in vivo role and proliferation is still unpredicted.^[21]

Other factors that enhance cervical cancer include impaired immune response, persistence of virus, smoking and administration of steroid hormones.^[21] Loss of tumour suppressor genes and the activation of oncogenes may also play an important role. For cervical carcinogenesis, steroid hormones (estrogens and progesterone) play a role in the initiation and successful development of progression of the disease. Women who take estradiol have been reported to develop HSIL lesions that ultimately lead to the progressive one.^[22, 23] Estrogen affects the immune response as well.^[24, 25]

Haptoglobin which was an acute phase glycoprotein present in body fluids is reported to be in relation with tumour and infection which modulate the Th1/Th2 response.^[26-29] The same factors are considered responsible for the immune tolerance related to human fertility.^[26, 27, 30] Apart from these mechanisms the genetic Hp polymorphism greatly enhances the female susceptibility for HPV cervical infection and neoplasia but also shows its relative response to the environmental cofactors such as sex steroid hormones ingestion which can be in the form of both hormone replacement therapy and oral contraceptive.^[26, 27] Keeping in view the other related factors the most prominent evidence for cervical cancer reported 80% of the studies are sexual behaviour and the changes related in sexual behaviour. The factor of sexual behaviour suffers lack of data, but according to the reported data on the subject, the increased ratio of CIN incidence among women ranging between 25 to 39 years. It may be due to the drastic changes in immigration, mixing patterns of population, population migration and economic migration.^[28]

HPV 16 among men

HPV affects not only women, but this virus is even contracted by men. Men do have the ability to transmit it but unlike women in men there is no such confirmed lab test available such as women do have Pap smear tests.^[31]

HPV16 among women

HPV16 which ultimately leads to cervical cancer stays and incubates in the body for a prolonged period of time before the onset of malignant cervical cancer.^[32] Sometimes it stays inside the body for years. The reason of development of cervical cancer is that keratinocytes infected with HPV16 do not have the capability to differentiate like normal cells and they have close resemblance of just the precancerous cervical lesions, upporting the association between infection with specific high risk HPV types and the precancerous lesions. These cells are supposed to be not always malignant or with a tumorigenic potential but its induction to lead towards malignancy by the activation of certain oncogenes it can lead to malignancy.^[33] They are now known to be the most prevalent etiological agents of cervical and various other anogenital malignancies. The human papilloma viruses are specifically released by the desquamating superficial keratinocytes of the infected stratified epithelia.^[34] Its transmission can vary in aspects such as direct contact and indirect contact. Direct contact could be a result of contact with infected tissue and the indirect contact can be with contact of contaminated objects or surfaces for eg: pool sides. The transmission of genital HPV is related specifically with sexual contact. The viral entry leads to a latent infection which develops within the first three months or it can remain undetected for years. The lesions are due to spread because of the infected cells.^[35]

Cervical cancer the 2nd most malignancy and its relation with HPV16

Cervical cancer can also be defined as the cancer originating at the opening of the womb which progressively migrates to the whole of cervix.^[36] HPV16 is known to cause cervical cancer and accounts for the majority of cervical carcinomas in United States and Europe.^[36, 37] HPV16 is roughly in half of the cervical cancers and their proteins have been detected extensively in HPV16 and are under observation. HPV 16 is one of the high-risk HPV infections particularly and causes cervical lesions specifically. The two proteins which play a significant role in onset of this malignancy are E6 and E7 proteins and their expression has been seen in the cell lines.^[37] IgG and IgA antibodies are associated with HPV16 and are found in CIN in a ratio of about 50-75%. Very few antibodies are detected in patients who have precancerous cervical lesion.

Back in 1977 statistical data suggested that HPV viruses are present in cervical epithelium.^[38] In different cervical smears and biopsies from women who had CIN, koilocytes were noted which proved that wart virus antigen and HPV DNA nuclei of cervical epithelial cells

are associated with cervical cancer. These observations lead to a platform for further research in this area.^[39] The precancerous lesions of CIN2 and CIN3 have shown positive results for HPV high risk viruses that develop into invasive cancer. Apart from HPV 16 and HPV18, other strains such as HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 leads progressively to invasive cervical cancer whereas mostly low risk HPV types can lead to condylomata. Analysis from several recent reports state that HPV 16/18 have a remarkable ability to immortalize keratinocytes and exhibit a drastic pattern of differentiation.

The most striking and promising evidence that human papillomaviruses play a pivotal role in oncogenesis is based on different patterns of HPV DNA in cervical cells and its integration. The result of integration is disruption of E1 and E2 gene expression which control the genes and deregulation of E6 and E7 open reading frames. The normal function of tumour suppressor genes p53 and Rb is blocked by the products of E6 and E7 coding regions.^[40]

Abbreviations

HPV: Human Papiloma virus.

FTP: Full Term Pregnancy ASCUS: atypical squamous cells are of undetermined significance.

CRN: cervical intraepithelial neoplasia.

REFERENCES

1. Review of Medical Microbiology and Immunology 10th edition. Edited by: Warren Levinson. Mc GrawHill, 2008; 270-275.
2. Molecular biologists for Oncologists 2nd edition. Edited by: Yarnold JR, Stratton MR, McMILLAN TJ. Chapman and Hall, 1996; 83-88.
3. Khan S, Jaffer NN, Khan MN, Rai MA, Shafiq M, Ali A, Pervez S, Khan N, Aziz A, Ali SH: Human papillomavirus subtype 16 is common in Pakistani women with cervical carcinoma. *Int J Infect Dis*, 2007; 11: 313-317. 10.1016/j.ijid. 2006.06.007 Article CAS PubMed Google Scholar.
4. Yasmeen A, Alachkar A, Dekhil H, Gambacorti-Passerini C, Al Moustafa AE: Locking Src/Abl Tyrosine Kinase activities regulate cell Differentiation and Invasion of Human cervical cancer cells expressing E 6 /E 7 oncoproteins of High-risk HPV. *J Oncol*, 2010; 2010: 10. Article Google Scholar.
5. Stone MK, Karem LK, Sternberg RM, McQuillan MG, Poon DA, Unger RA, Reeves CW: Seroprevalence of human papillomavirus type 16 infection in the United States. *J Infect Dis*, 2002; 186: 1396-1402. 10.1086/344354 Article PubMed Google Scholar.
6. Porass C, Bennett C, Safaeian M, Coseo S, Rodriguez AC, González P, Hutchinson M, Jimenez S, Sherman ME, Wacholder S, Solomon D, Doorn Leen-Jan V, Bougelet C, Quint W, Schiffman M, Herrero R, Hildesheim A: Determinants of

- Seropositivity among HPV16/18DNA positive young women. *BMC Infect Dis*, 2010; 10: 238. Google Scholar
7. Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, Roden RBS, Meyers C: Tissue-spanning redox gradient-dependant assembly of native human papilloma virus type 16 virions. *J virol*, 2009; 83: 10515-10526. 10.1128/JVI.00731-09 PubMed Central Article CAS PubMed Google Scholar
 8. *Microbiology and molecular biology reviews*, 2004; 68(2): 1092-2172.
 9. Gao P, Zheng J: High-risk HPV E 5 – induced cell fusion a critical initiating event in the early stage of HPV-associated cervical cancer. *J Virol*, 2010; 7: 238.10.1186/1743-422X-7-238 Article Google Scholar
 10. Nariseuva Saito M, et al.: Basic mechanisms of High-risk human papilloma virus induced carcinogenesis. *Cancer Science*, 2007; 98: 1505-1511. 10.1111/j. 1349-7006.2007.00546.x Article Google Scholar
 11. Tsai TC, Chen SL: The biochemical and biological functions of human papilloma virus type16 E 5 protein. *Archives Virology*, 2003; 148: 1445-1453. 10.1007/s00705-003-0111-z Article CAS Google Scholar
 12. Zeffass D, et al.: Sequential activation of cyclin E and cyclin A gene expression by human papilloma virus type 16E 7 through sequences necessary for transformation. *J Virol*, 1995; 69: 6389-6399. PubMed Central CAS PubMed Google Scholar
 13. Gagnon D, Joubert S, Senechal H, Fradet-Turcotte A, Torre S, Archambault J: Proteasomal degradation of the papillomavirus E 2 protein is inhibited by overexpression of bromodomain containing protein 4. *J Virol*, 2009; 83: 4127-4139. 10.1128/JVI.02468-08 PubMed Central Article CAS PubMed Google Scholar
 14. Muller Schiffmann A, Beckmann J, Steger G: The E 6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms. *J Virol*, 2006; 80: 8718-8728. 10.1128/JVI.00250-06 PubMed Central Article PubMed Google Scholar
 15. Lace MJ, Anson JR, Thomas GS, Turek LP, Haugen TH: The E 8 {wedge}E 2 gene product of human papillomavirus type 16 represses early transcription of replication but is dispensable for viral plasmid persistence in Keratinocytes. *J Virol*, 2008; 82: 10841-10853. 10.1128/JVI. 01481-08 PubMed Central Article CAS PubMed Google Scholar.
 16. Incassati A, Patel D, McCance DJ: Induction of Tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type 16 E 6 . *Oncogene*, 2006; 25: 2444-2451. 10.1038/sj.onc.1209276 Article CAS PubMed Google Scholar.
 17. Darnell GA, Schroder WA, Antalis TM, Lambley E, Major L, Gardner J, Birell G, Suhrbier A: Human papilloma virus E 7 requires the protease calpain to degrade the retinoblastoma protein. *J Biol Chem*, 2007; 282: 37492-37500. 10.1074/ jbc.M706860200 Article CAS PubMed Google Scholar
 18. Zhang B, Chen W, Roman A: The E 7 proteins of low and high-risk human papilloma viruses share the ability to target the pRb family member p130 for degradation. *Proc Natl Acad Sci*, 2006; 103: 437-442. 10.1073/pnas. 0510012103 PubMed Central Article CAS PubMed Google Scholar
 19. Dyson N, Howley PM, K M, Harlow E: The human papilloma virus E 7 oncoprotein is able to bind to the retinoblastoma gene product. *Science*, 1987; 243: 934-937. Article Google Scholar
 20. Smith JS, Lindsay L, Hoots B, Keys J, Franceschin S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta analysis update. *Int J Cancer*, 2007; 3: 621-632. Article Google Scholar
 21. Stanely M: Immune responses to human papillomavirus. *Vaccine* 2006,24(suppl1):S 10-16. Google Scholar
 22. de Villiers EM: Relation ship between steroid hormone contraceptives and HPV cervical intraepithelial neoplasia and cervical carcinoma. *Int J Cancer*, 2003; 103: 705-708. 10.1002/ijc. 10868 Article CAS PubMed Google Scholar
 23. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM: Sensitivity of the cervical transformation zone to estrogen induced squamous carcinogenesis. *Cancer Research*, 2000; 60: 1267-1275. CAS PubMed Google Scholar
 24. Paavonen T, Andersson LC, Adlercreutz H: Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen stimulated cultures. *J E M*, 1981; 154: 1935-1945. 10.1084/jem.154.6.1935 Article CAS Google Scholar
 25. Hughes GC, Clark EA: Regulation of Dendritic cells by female sex steroids: relevance to immunity and auto immunity. *Auto immunity*, 2007; 40: 470-481. CAS Google Scholar
 26. Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin in human. *Eur J Clin Chem* 1996, 42: 1589-1600. CAS Google Scholar
 27. Quaye IK: Haptoglobin inflammation and disease. *Trans R soc trop medi hyg*, 2008; 102: 735-742. 10.1016/j.trstmh. 2008.04.010 Article CAS Google Scholar
 28. Vilerberghe HV, Langlois M, Delanghe J: Haptoglobin polymorphisms and iron homeostasis in health and in disease. *Clin chimica Acta*, 2004; 345: 35-42. 10.1016/ j.cccn.2004.03.016 Article Google Scholar
 29. Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP: Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free haemoglobin. *Artherosclerosis*,

- 2007; 191: 48-53. 10.1016/j.atherosclerosis.2006.04.032 Article CAS Google Scholar
30. Bottini N, Gimelfarb A, Gloria-Bottini F, La Torre M, Lucarelli P, Lucarini N: Haptoglobin genotype and natural fertility in humans. *Fertility and Sterility*, 1999; 72: 293-296. 10.1016/S0015-0282(99)00210-1 Article CAS Google Scholar
31. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR: Prevalence of HPV infection among men: Asystematic review of the literature. *J infect dis*, 2006; 194: 1044-1057. Article Google Scholar
32. Ho Gloria YF, Studentsov YY, Bierman R, D Burk R: Natural history of human papillomavirus type 16 virus like particle antibodies in young women. *Cancer Epidemiology, Biomarkers and Prevention*, 2004; 13: 110-116. 10.1158/1055-9965.EPI-03-0191 Article CAS PubMed Google Scholar
33. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD: The carcinogenicity of human papillomavirus types reflects viral evolution. *Virology*, 2005; 337: 76-84.10.1016/j.virol.2005.04.002 Article CAS PubMed Google Scholar
34. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, Park S, Touzé A, Muñoz N, Snijders PJ, Meijer CJ, Coursaget P, Franceschi S: Prevalence of human papillomavirus infection in women in Busan, South Korea. *Int J Cancer*, 2003; 103: 413-421. 10.1002/ijc.10825 Article CAS PubMed Google Scholar
35. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. *New Eng J Med*, 2003; 348: 518-527. 10.1056/NEJMoa021641 Article PubMed Google Scholar
36. Müller-Schiffmann A, Beckmann J, Steger J: The E6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanism. *J virol*, 2006; 80: 8718-8728. 10.1128/JVI.00250-06 PubMed Central Article PubMed Google Scholar
37. Herdman MT, Pett MR, Roberts I, Alazawi WO, Teschendorff AE, Zhang XY, Stanley MA, Coleman N: Interferon- β treatment of cervical keratinocytes naturally infected with human papillomavirus16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. *Carcinogenesis*, 2006; 27: 2341-2353. 10.1093/carcin/bgl172 Article CAS PubMed Google Scholar.
38. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The casual relationship between human papillomavirus and cervical cancer. *J clin Pathol*, 2002; 55(4): 244-265. 10.1136/jcp.55.4.244 PubMed Central Article CAS PubMed Google Scholar.
39. Frazer IH: Interaction of human papillomavirus with the host immune system:a well evolved relationship. *Virology*, 2009; 384(2): 410-414. 10.1016/j.virol.2008.10.004 Article CAS PubMed Google Scholar
40. Darnell GA, Schroder WA, Antalis TM, Lambley E, Major L, Gardner J, Birrell G, Cid-Arregui A, Suhrbier A: Human papillomavirus E7 requires the protease Calpain to degrade the Retinoblastoma Protein. *J Bio Chem*, 2007; 282: 37492-37500. 10.1074/jbc.M706860200 Article CAS Google Scholar